Thoughts on COVID-19 and autoimmune diseases

Over the 2 months since coronavirus first appeared in China, cases have emerged on every continent, and it is clear that patients with autoimmune diseases might also be affected. Coronavirus disease 2019 (COVID-19) is a highly contagious viral illness with a mortality rate approaching 2%. Here we di...

Descripción completa

Detalles Bibliográficos
Autores principales: Askanase, Anca D, Khalili, Leila, Buyon, Jill P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174058/
https://www.ncbi.nlm.nih.gov/pubmed/32341791
http://dx.doi.org/10.1136/lupus-2020-000396
_version_ 1783524559811510272
author Askanase, Anca D
Khalili, Leila
Buyon, Jill P
author_facet Askanase, Anca D
Khalili, Leila
Buyon, Jill P
author_sort Askanase, Anca D
collection PubMed
description Over the 2 months since coronavirus first appeared in China, cases have emerged on every continent, and it is clear that patients with autoimmune diseases might also be affected. Coronavirus disease 2019 (COVID-19) is a highly contagious viral illness with a mortality rate approaching 2%. Here we discuss the challenges that patients with autoimmune diseases might face and the information on using immunomodulatory therapies like chloroquine, tocilizumab and baricitinib to quench the cytokine storm in patients with very severe COVID-19 pneumonia.
format Online
Article
Text
id pubmed-7174058
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-71740582020-04-27 Thoughts on COVID-19 and autoimmune diseases Askanase, Anca D Khalili, Leila Buyon, Jill P Lupus Sci Med Letter Over the 2 months since coronavirus first appeared in China, cases have emerged on every continent, and it is clear that patients with autoimmune diseases might also be affected. Coronavirus disease 2019 (COVID-19) is a highly contagious viral illness with a mortality rate approaching 2%. Here we discuss the challenges that patients with autoimmune diseases might face and the information on using immunomodulatory therapies like chloroquine, tocilizumab and baricitinib to quench the cytokine storm in patients with very severe COVID-19 pneumonia. BMJ Publishing Group 2020-04-03 /pmc/articles/PMC7174058/ /pubmed/32341791 http://dx.doi.org/10.1136/lupus-2020-000396 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Letter
Askanase, Anca D
Khalili, Leila
Buyon, Jill P
Thoughts on COVID-19 and autoimmune diseases
title Thoughts on COVID-19 and autoimmune diseases
title_full Thoughts on COVID-19 and autoimmune diseases
title_fullStr Thoughts on COVID-19 and autoimmune diseases
title_full_unstemmed Thoughts on COVID-19 and autoimmune diseases
title_short Thoughts on COVID-19 and autoimmune diseases
title_sort thoughts on covid-19 and autoimmune diseases
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174058/
https://www.ncbi.nlm.nih.gov/pubmed/32341791
http://dx.doi.org/10.1136/lupus-2020-000396
work_keys_str_mv AT askanaseancad thoughtsoncovid19andautoimmunediseases
AT khalilileila thoughtsoncovid19andautoimmunediseases
AT buyonjillp thoughtsoncovid19andautoimmunediseases

Ejemplares similares